Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale.
Researchers have developed gold nanoparticles that could act as a cancer treatment by heating up and destroying tumor cells when they absorb near-infrared light. And the scientists have made the so-called plasmonic particles in a way that can be reproduced in bulk.
Every living cell stores or spends its energy in the form of adenosine triphosphate, or ATP, which has historically been known as the "molecular unit of currency." And using this molecule as a targeting mechanism for cancer drugs, scientists in North Carolina have developed a way to trigger the release of chemotherapy within the offending cells.
Researchers at Shanghai Jiao Tong University in China have developed nanoparticles capable of crossing the blood-brain barrier that could potentially help to clear amyloid-β proteins, which are associated with Alzheimer's disease.
Research in drug delivery is shifting further and further to the nano scale, and while nanotechnology still hovers for the most part just short of the clinical stage, new techniques in manufacturing the particles are crucial to bringing them to the next step.
To tackle difficult-to-treat drug-resistant ovarian cancer, researchers at Tel Aviv University have developed nanoparticles designed to accumulate in clusters in tumors to deliver chemotherapy, increasing efficacy and reducing side effects.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a light-activated delivery system for chemotherapy.
Researchers in China published an article in the journal Biomedical Materials demonstrating the drug-delivery potential of new gold nanoshells for cancer that also use hyperthermic effects to bring toxic cancer drugs to tumors with fewer side effects.
Scientists from Alnylam teamed with MIT researchers to develop a new nanoparticle platform with which to better deliver the genetic material to the liver. With MIT professor Robert Langer as one of its authors, the team published a paper in the journal Proceedings of the National Academy of Sciences highlighting its particles, which are inspired by the vehicles the body uses to transport cholesterol.
Patients with muscular dystrophy suffer from the dysfunction of the gene that produces dystrophin, which is a protein that maintains muscle cells' performance. And a team of researchers from Washington University School of Medicine in St. Louis has found that another factor might also play a role in the weakened muscles: The cells aren't properly recycling their waste.